Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China

References

• Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. doi:10.1016/j.diabres.2019.107843
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310:948–959. doi:10.1001/jama.2013.168118
   PubMed Web of Science ®Google Scholar
• Sarwar N, Gao P, Gobin R, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 375;2010:2215–2222. doi:10.1016/S0140-6736(10)60484-9
   PubMed Web of Science ®Google Scholar
• Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–841.
   PubMed Web of Science ®Google Scholar
• Bancks MP, Ning H, Allen NB, et al. Long-term absolute risk for cardiovascular disease stratified by fasting glucose level. Diabetes Care. 2019;42:457–465. doi:10.2337/dc18-1773
   PubMedGoogle Scholar
• Di Angelantonio E, Kaptoge S, Wormser D; Emerging Risk Factors Collaboration, et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 314;2015:52–60. doi:10.1001/jama.2015.7008
   PubMedGoogle Scholar
• ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412. doi:10.1136/bmj.321.7258.405
   PubMed Web of Science ®Google Scholar
• Kassem SA, Raz I. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No. Diabetes Care. 2009;32(Suppl 2):S337–S341. doi:10.2337/dc09-S335
   PubMed Web of Science ®Google Scholar
• Bianchi C, Miccoli R, Daniele G, Penno G, Del Prato S. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. Diabetes Care. 2009;32(Suppl 2):S342–S348. doi:10.2337/dc09-S336
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471. doi:10.1056/NEJMoa072761
   PubMed Web of Science ®Google Scholar
• Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011;32:63–71. doi:10.1016/j.tips.2010.11.011
   PubMed Web of Science ®Google Scholar
• Chao EC, Henry RR. SGLT2 inhibition – a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9:551–559. doi:10.1038/nrd3180
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, Norton L, DeFronzo RA. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol. 2015;309:F889–F900. doi:10.1152/ajprenal.00267.2015
   PubMed Web of Science ®Google Scholar
• Mudaliar S, Polidori D, Zambrowicz B, Henry RR. Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care. 2015;38:2344–2353. doi:10.2337/dc15-0642
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128. doi:10.1056/NEJMoa1504720
   PubMed Web of Science ®Google Scholar
• Nguyen E, Coleman CI, Nair S, Weeda ER. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk. J Diabetes Complications. 2018;32:210–215. doi:10.1016/j.jdiacomp.2017.10.006
   PubMed Web of Science ®Google Scholar
• Kansal A, Reifsnider OS, Proskorovsky I, et al. Cost-effectiveness analysis of empagliflozin treatment in people with type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial. Diabet Med. 2019;36:1494–1502. doi:10.1111/dme.14076
   PubMedGoogle Scholar
• Gourzoulidis G, Tzanetakos C, Ioannidis I, et al. Cost-effectiveness of empagliflozin for the treatment of patients with type 2 diabetes mellitus at increased cardiovascular risk in Greece. Clin Drug Invest. 2018;38:417–426. doi:10.1007/s40261-018-0620-x
   PubMed Web of Science ®Google Scholar
• Kaku K, Haneda M, Sakamaki H, et al. Cost-effectiveness analysis of empagliflozin in Japan based on results from the Asian subpopulation in the EMPA-REG OUTCOME trial. Clin Ther. 2019;41:2021–2040. doi:10.1016/j.clinthera.2019.07.016
   PubMedGoogle Scholar
• Sullivan PW, Ghushchyan VH. EQ-5D scores for diabetes-related comorbidities. Value Health. 2016;19:1002–1008. doi:10.1016/j.jval.2016.05.018
   PubMed Web of Science ®Google Scholar
• Zheng YM. Methodology and empirical study on the economic burden of diabetes mellitus. Tianjin Univ. 2012.
   Google Scholar
• Wang HY. Screening strategy and cost-effectiveness analysis by Markov model for persistent albuminuria among high risk population with chronic kidney disease. Zhengzhou Univ. 2015.
   Google Scholar
• Xie XQ, Vondeling H. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China. Value Health. 2008;11:S23–S32. doi:10.1111/j.1524-4733.2008.00363.x
   PubMed Web of Science ®Google Scholar
• Fang Y, Ding XQ, Zhang YH, et al. Acute kidney injury in a Chinese hospitalized population. Blood Purif. 2010;30:120–126. doi:10.1159/000319972
   PubMed Web of Science ®Google Scholar
• Chen XB, Tang L, Chen HY, Zhao LY, Hu SL. Assessing the impact of complications on the costs of type 2 diabetes in urban China. Chin J Diabetes. 2003;11:238–241.
   Google Scholar
• Zhang TT. The ischemic attack patient’s hospitalization expense made and influence factors analysis. Dalian Med Univ. 2010.
   Google Scholar
• National Health Commission. China Health Statistics Yearbook (2018). Beijing: Peking Union Medical College Press; 2018.
   Google Scholar
• World Health Organization. Choosing interventions that are cost effective (WHO-CHOICE): cost-effectiveness thresholds; 2013. Available from:http://www.who.int/choice/costs/CER_thresholds/en/index.html. Accessed November 13, 2018.
   Google Scholar
• National Bureau of statistics. Statistical communiqué of the People’s Republic of China on 2017 national economic and social development; 2018. Available from: http://www.stats.gov.cn/tjsj/zxfb/201802/t20180228_1585631.html. Accessed November 30, 2018.
   Google Scholar
• Kansal A, Zheng Y, Proskorovsky I, Krotneva S, Kandaswamy P, Ruffolo A. Modeling cardiovascular outcomes of treatment with empagliflozin in type 2 diabetes based on hard outcomes data. Value Health. 2016;19:A203. doi:10.1016/j.jval.2016.03.1299
   Google Scholar
• Rahman W, Solinsky PJ, Munir KM, Lamos EM. Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2018;9:1–11.
   Google Scholar
• Henkhaus LE, Hay JW. Cost effectiveness of empagliflozin/linagliptin as 2nd-line therapy for adults with type 2 diabetes. Value Health. 2016;19:A202–A203. doi:10.1016/j.jval.2016.03.1297
   PubMed Web of Science ®Google Scholar
• Pawlik D, Wójcik R, Zawodnik A, Kaczor MP. Cost-effectiveness of empagliflozin in patients with type 2 diabetes mellitus at high cardiovascular risk in Poland. Value Health. 2017;20:A478. doi:10.1016/j.jval.2017.08.453
   Web of Science ®Google Scholar
• Daacke I, Kandaswamy P, Tebboth A, Kansal A, Reifsnider O. Cost-effectiveness of empagliflozin (Jardiance) in the treatment of patients with type 2 diabetes mellitus (T2DM) in the UK based on EMPA-REG outcome data. Value Health. 2016;19:A673. doi:10.1016/j.jval.2016.09.1876
   Web of Science ®Google Scholar
• Mettam SR, Bajaj H, Kansal AR, Kandaswamy P. Cost effectiveness of empagliflozin in patients with T2DM and high CV risk in Canada. Value Health. 2016;19:A674. doi:10.1016/j.jval.2016.09.1882
   Web of Science ®Google Scholar
• Iannazzo S, Mannucci E, Reifsnider O, Maggioni AP. Cost-effectiveness analysis of empagliflozin in the treatment of T2D with previous cardiovascular disease in Italy. Value Health. 2017;20:A480–A481. doi:10.1016/j.jval.2017.08.464
   Web of Science ®Google Scholar
• Oksuz E, Malhan S, Kamaci E, et al. Cost-effectiveness of empagliflozin (Jardiance®) in the treatment of patients with type 2 diabetes mellitus (T2DM) in Turkey based EMPA-REG outcome data. Value Health. 2017;20:A479. doi:10.1016/j.jval.2017.08.457
   Web of Science ®Google Scholar
• Aguiar-Ibáñez R, Palencia R, Kandaswamy P, Li L. Cost-effectiveness of empagliflozin (Jardiance®) 10 mg and 25 mg administered as an add-on to metformin and sulfonilurea (Met+SU) compared to other sodium-glucose co-transporter 2 inhibitors (SGLT2Is) in patients with type 2 diabetes mellitus (T2DM) in the UK. Value Health. 2014;17:A351.
   PubMed Web of Science ®Google Scholar
• Aguiar-Ibáñez R, Palencia R, Kandaswamy P, Li L. Cost-effectiveness of empagliflozin (Jardiance®) 10 mg and 25 mg administered as an add-on to metformin compared to other sodium-glucose co-transporter 2 inhibitors (SGLT2Is) for patients with type 2 diabetes mellitus (T2DM) in the UK. Value Health. 2014;17:A350–1. doi:10.1016/j.jval.2014.08.729
   PubMed Web of Science ®Google Scholar
• Carrasco Perez M, Male N, Serra Burriel M, Pfarr E, Kansal A. Indirect cost-effectiveness analysis of empagliflozin compared to canagliflozin for patients with T2DM and cardiovascular disease in the Spanish National Health Service. Value Health. 2018;21:S130. doi:10.1016/j.jval.2018.09.778
   Google Scholar
• Lamotte M, Ramos M, Salem A, et al. Cost-effectiveness analysis of empagliflozin in comparison to liraglutide based on cardiovascular outcome trials. Value Health. 2018;21:S131. doi:10.1016/j.jval.2018.09.781
   PubMedGoogle Scholar
• Huicochea-Bartelt JL, Vargas-Valencia JJ, Herran S. Cost-effectiveness (CE) analysis of empagliflozin 25mg versus sitagliptin 100mg in the treatment of patients with type 2 diabetes mellitus (T2DM) when added to metformin (MET) from a Mexican public institutional context. Value Health. 2015;18:A61. doi:10.1016/j.jval.2015.03.359
   PubMedGoogle Scholar
• Gorgojo-Martínez JJ, Malkin SJP, Martín V, Hallén N, Hunt B. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: once-weekly semaglutide versus empagliflozin. J Med Econ. 2020;23:193–203. doi:10.1080/13696998.2019.1681436
   PubMed Web of Science ®Google Scholar
• Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43:487–493. doi:10.2337/dci19-0066
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323.
   PubMed Web of Science ®Google Scholar
• Jia W, Weng J, Zhu D, et al. Standards of medical care for type 2 diabetes in China 2019. Diabetes Metab Res Rev. 2019;35:e3158. doi:10.1002/dmrr.3158
   PubMed Web of Science ®Google Scholar